The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Phospha 250 Neutral
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate · SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg/1; POTASSIUM PHOSPHATE, MONOBASIC 155 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg/1 · Tablet · Oral · Rising Pharma Holdings, Inc.
NDC 64980-0729-01 · 100 TABLET in 1 BOTTLE · UNAPPROVED DRUG OTHER · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for dibasic sodium phosphate, monobasic potassium phosphate and monobasic sodium phosphate (oral solid) in the next 90 days
price up 66% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- Ingenus Pharmaceuticals NJ, LLCUnited Statesmanufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Rising Pharma Holdings, Inc. | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg/1; POTASSIUM PHOSPHATE, MONOBASIC 155 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Rising Pharma Holdings, Inc. | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 155 mg/1; POTASSIUM PHOSPHATE, MONOBASIC 852 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg/1 | Jul 22, 2026 | Aug 22, 2026 |
| Rising Pharma Holdings, Inc. | POTASSIUM PHOSPHATE, MONOBASIC 155 mg/1; SODIUM PHOSPHATE, DIBASIC, ANHYDROUS 852 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 130 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Phospha 250 Neutral — NDC 64980-0729-01," retrieved September 3, 2026, https://drugdashboards.com/drug/64980072901.
Free to cite with attribution — see how the data is put together.